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Effects of Intronic and Exonic Polymorphisms of Paraoxonase 1 
(PON1) Gene on Serum PON1 Activity in a Korean Population
Paraoxonase 1 (PON1) hydrolyzes a number of toxic organophosphorous compounds and 
reduces lipid peroxide accumulation, and PON1 genetic polymorphisms in the coding 
region modulate serum PON1 activity. In this study, we investigated the association 
between 3 polymorphisms of PON1 located in intron 5 (17899insdelTT and 17974CT) and 
exon 6 (192QR) and serum PON1 activity. The genetic polymorphisms and serum activity 
of PON1 were analyzed in 153 healthy Koreans by using a direct sequencing assay and 
spectrophotometric method, respectively. A significant linkage disequilibrium (LD) was 
observed between all tested single nucleotide polymorphisms, with the strongest LD 
observed between 17899insdelTT and 192QR (D’ = 0.984). The 17899insdelTT, 17974CT 
and 192QR genetic polymorphisms were associated with significant differences in serum 
paraoxonase activity. In multiple regression analyses, smoking, triglyceride level, high-
density lipoprotein (HDL) level, and the 17899insdelTT and 192QR genetic polymorphisms 
were significant determinants of serum paraoxonase activity, while age, smoking, 
triglyceride level, HDL level, and the 192QR genetic polymorphism were significant 
determinants of serum arylesterase activity. These results suggest that although the 192QR 
genetic polymorphism in the coding region of PON1 is primarily associated with serum 
PON1 activity, the intronic polymorphisms are also involved in serum PON1 activity, and 
this association may be mediated by LD.
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INTRODUCTION
The human paraoxonase (PON) multigene cluster is located on 
the long arm of chromosome 7 at q21–q22 and includes 3 mem-
bers-PON1, PON2, and PON3-adjacent to each other (1). PON1 
is a high-density lipoprotein (HDL)-associated serum enzyme 
composed of 354 amino acids (43 kDa) and the most abundant 
PON enzyme. PON1 and PON3 are predominantly expressed 
in the liver and secreted into blood (1-3). PON2 is more widely 
expressed in a number of tissues including the brain, liver, kid-
ney, and testis but not detectable in the blood (4). Among them 
PON1 only has paraoxonase and arylesterase activities, and 
PON2 and PON3 lack these activities (3). It is well known that 
PON1 hydrolyzes the oxons (e.g., paraoxon, diazoxon, and chlor-
pyrifos oxon) which are toxic metabolites of organophosphate 
pesticides. In addition, PON1 plays an antioxidant role in lipid 
metabolism by inhibiting the oxidation of low-density lipopro-
tein (LDL) and preventing lipid peroxide accumulation on LDL 
(4-6). These actions of PON1 exert a protective effect on the ear-
ly progression of cardiovascular disease and atherosclerosis (2).
  About 200 single nucleotide polymorphisms (SNPs) have 
been identified in the human PON1 gene. These are located in 
the promoter (7 SNPs), intronic (171 SNPs), exonic (5 SNPs), and 
3´-untranslated regions (15 SNPs) (7). Most studies have focused 
on the associations between genetic polymorphisms in the PON1 
promoter region (-108CT and -162AG) and coding region (55LM 
and 192QR) and on PON1’s catalytic activity, which is associat-
ed with susceptibility to certain pesticides and cardiovascular 
diseases (2-6). The PON1-108CT polymorphism in the promot-
er region is in linkage disequilibrium (LD) with the 55LM poly-
morphism and is related to variation in plasma PON1 expres-
sion levels (8). The PON1 192QR genetic polymorphism has been 
shown to produce a substrate-dependent difference on the cat-
alytic efficiency of PON1. In in vitro studies, the PON1 192 R   
allele hydrolyzes paraoxon more efficiently than the Q allele, 
whereas diazoxon, sarin, and soman are hydrolyzed more rap-
idly by the Q allele (9). In the 3´ end region of intron 5, adjacent 
to the PON1 192QR polymorphic site, 2 intronic polymorphisms 
exist at position 17899 (17899insdelTT, SNP ID: rs3917539) and 
17974 (17974CT, SNP ID: rs3917541) of the PON1 gene. To date, 
intronic genetic polymorphisms of PON1 have not been char-
acterized, although they are suspected of being involved in the Eom S-Y, et al.  •  PON1 Genetic Polymorphisms and Serum PON1 Activity
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regulation of enzyme activity through interfering with the cor-
rect splicing of the gene’s mRNA (3). 
  PON1 phenotype can be measured by a two-substrate assay 
that uses the substrate pair-paraoxon and phenylacetate (10). 
Individual PON1 paraoxonase and arylesterase activities have 
been shown to be affected by genetic polymorphisms of PON1 
and various environmental factors (2). 
  In this study, we analyzed the frequencies of 3 PON1 genetic 
polymorphisms in intronic (17899insdelTT and 17974CT) and 
exonic (192QR) regions, and evaluated the influence of intronic 
and exonic genetic polymorphisms of PON1 on serum enzyme 




Subjects of this study consisted of 153 healthy individuals who 
received routine medical examinations at Chungbuk National 
University Hospital, Korea. Trained interviewers collected in-
formation on demographic factors, smoking habits, alcohol con-
sumption, and occupational history, using a structured ques-
tionnaire. Peripheral blood was collected in both an EDTA-treat-
ed tube and a serum separator tube for DNA preparation and 
the PON1 activity assay, respectively. 
PON1 genotyping
Genomic DNA was isolated from peripheral blood using a DNA 
Extractor WB Kit (Wako, Osaka, Japan) according to the manu-
facturer’s protocol. The region of PON1 including the intronic 
(17899insdelTT and 17974CT) and exonic (192QR) SNP sites 
was amplified using primers 5´-TGT TAC AGT GCT ATA ATC 
ACC TCC-3´ and 5´-CCA AGA TAT CTC CTG AGA ATC TGA-3´ 
in a thermal cycler (TaKaRa, Shiga, Japan). The PCR were per-
formed in 25 µL PCR reaction solution containing 50 ng of ge-
nomic DNA, 10 × PCR buffer (Roche Applied Science, Indianap-
olis, IN, USA), 5 pM of each primer, 200 µM each dNTP and 0.025 
unit FastStart Taq DNA polymerase (Roche Applied Science). 
Thermal cycling was carried out as follows: 5 min of denatur-
ation at 94°C, then 35 cycles consisting of denaturation at 94°C 
for 30 sec, annealing at 52°C for 30 sec, and extension at 72°C 
for 45 sec. Unincorporated dNTPs and primers in the PCR prod-
uct (484 bp fragments) were purified with a purification kit (Real 
Biotech Corporation, Banqiao, Taiwan). Intronic and exonic 
SNPs of PON1 were determined by a fluorescent dye termina-
tor method using an ABI PRISM BigDye Terminator Cycle Se-
quencing Ready Reaction Kit and an ABI 3730XL capillary DNA 
Sequencer (Applied Biosystems, Carlsbad, CA, USA).
PON1 enzyme activity assays 
Serum PON1 enzyme activity was determined by a spectropho-
tometeric method using 2 substrates-paraoxon and phenylace-
tate (10). For measurement of PON1-paraoxonase activity, 190 
µL of the substrate (1.2 mM paraoxon, 0.26 mM Tris-HCl at pH 
8.5, 25 mM CaCl2, and 500 mM NaCl) was mixed with 10 µL of 
diluted serum. Enzyme activity was calculated using the rate       
of p-nitrophenol production monitored at 405 nm and was ex-
pressed in units/mL on the basis of the molar extinction coeffi-
cient of 18/mM/cm for p-nitrophenol. 
  PON1-arylesterase activity was measured in 190 µL of the sub-
strate (3.26 mM phenyl acetate, 9 mM Tris-HCl at pH 8 and 0.9 
mM CaCl2) mixed with 10 µL of diluted serum. Enzyme activity 
was calculated using the rate of phenol production monitored 
at 270 nm and was expressed in units/mL based on the molar 
extinction coefficient of 1.31/mM/cm for phenol. Both enzyme 
activity assays were carried out in a SPECTRAmax PLUS micro-
plate spectrophotometer (Molecular Devices, Sunnyvale, CA, 
USA) as described previously (11). The assay value was correct-
ed for path-length using software provided with the microplate 
reader (12).
Statistical analysis 
Means of serum PON1 activity according to different genotypes 
were compared using analysis of variance (ANOVA) and t-tests. 
To test the effects of 3 genetic polymorphisms of PON1 on se-
rum PON1-paraoxonase or PON1-arylesterase activity, multi-
ple regression models (stepwise selection) that included inde-
pendent variables (e.g. gender, age, smoking, alcohol consump-
tion, triglyceride level, HDL-cholesterol level, LDL-cholesterol 
level, and body mass index) were used. LD statistics (D’ and chi-
square) for 3 genetic polymorphisms of PON1 were determined 
by using the SNP Analyzer V2.0 (ISTECH Inc., Goyang, Korea). 
All statistical analysis was performed using SPSS 12.0 for Win-
dows (SPSS company, Chicago, IL, USA).
Ethics statement
This study was approved by the institutional review board of 
Chungbuk National University, College of Medicine (IRB ap-
proval Number: CBNU-IRB-2009-BQ1). Written informed con-
sent was provided by all subjects.
 
RESULTS
General characteristics, lipid profile, and serum PON1 
activity of study subjects
The general characteristics, lipid profile, and serum PON1 ac-
tivity of study subjects are presented in Table 1. The mean age 
of study subjects was 66.7 ± 10.2 yr, 75% of all subjects were aged 
60 yr or older. The proportion of smokers and alcohol drinkers 
was significantly greater in men than in women, and LDL levels 
were significantly higher in women than in men. The means of 
serum PON1-paraoxonase and arylesterase activity were 241.8 
± 105.9 unit/L and 88.9 ± 24.0 unit/mL, respectively. The serum Eom S-Y, et al.  •  PON1 Genetic Polymorphisms and Serum PON1 Activity
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PON1-arylesterase activity of women was significantly higher 
than that of men (P < 0.05) (Table 1). 
Distribution of genotypes and alleles, and linkage 
disequilibrium analysis for PON1 SNPs
The distributions of the genotypes and alleles for PON1 intronic 
(17899insdelTT and 17974CT) and exonic (192QR) polymor-
phisms are presented in Table 2. All genotypes were in agree-
ment with Hardy-Weinberg equilibrium in this study (P > 0.05). 
The frequencies of major alleles of intronic (17899insTT and 
17974C) and exonic (192R) polymorphisms were 63%, 89%, and 
66%, respectively. We observed significant LD between all test-
ed SNPs, with the strongest LD found between SNPs 17899ins-
delTT and 192QR (D’ = 0.984) (Table 2). 
Effects of PON1 genetic polymorphisms on PON1 serum 
enzyme activity
Both the intronic and the exonic genetic polymorphisms were 
associated with significant differences in serum PON1-paraox-
onase activity. Serum PON1-paraoxonase activity was highest 
for the 17899insTT/insTT, 17974C/T or T/T, and 192R/R geno-
types and lowest for the 17899delTT/delTT, 17974C/C, and 192Q/ 
Q genotypes. The mean serum PON1-arylesterase activity was 
highest in individuals with the 17899delTT/delTT, 17974C/T or 
T/T, and 192Q/Q genotypes, respectively. The 17899insdelTT 
and 192QR polymorphisms were associated with significant dif-
ferences in serum PON1-arylesterase activity (Table 3). 
  Multiple regression analysis (stepwise selection) was used to 
assess determinants of serum PON1 activity (Table 4). Age was 
negatively correlated with serum PON1-paraoxonase activity 
with borderline significance (P = 0.091), and ever-smokers had 
lower serum PON1-paraoxonase activity than never-smokers (P 
= 0.005). Triglyceride and HDL-cholesterol were positively cor-
related with serum PON1-paraoxonase activity. Both intronic 
(17974CT) and exonic (192QR) polymorphisms were strongly 
associated with serum PON1-paraoxonase activity. Age, smok-
ing history, triglyceride and HDL concentrations, body mass 
index, and intronic (17899insdelTT and 17974CT) and exonic 
(192QR) polymorphisms explained 65.8% of the variance of se-
rum PON1-paraoxonase activity in this study (P < 0.001). The 
effect size of the 192QR polymorphism for serum PON1-para-
oxonase activity was about 53.7% and had the largest effect of 
any of the independent variables. PON1-arylesterase activity 
Table 1. General characteristics, lipid profile, and serum PON1 activity of the study 
population
Parameters All subjects Men Women
Number (No.) 153 26 127
Age (yr) 66.7 ± 10.2   68.0 ± 11.0  66.4 ± 10.1
Smoking (%) 13.3 61.5*   3.2
Alcohol drinking (%) 32.2 73.1* 23.8
Triglyceride (mg/dL)   161.9 ± 103.4   192.2 ± 133.3 155.7 ± 95.7
Total cholesterol (mg/dL) 201.6 ± 37.8 184.1 ± 42.4  205.2 ± 35.9*
HDL (mg/dL)   48.1 ± 13.3   48.1 ± 17.5   48.0 ± 12.4
LDL (mg/dL) 112.3 ± 33.6   93.7 ± 35.8  116.1 ± 31.9*
Paraoxonase (unit/L)   241.8 ± 105.9 240.8 ± 91.6   241.9 ± 108.9
Arylesterase (unit/mL)   88.9 ± 24.0   78.1 ± 23.8    91.1 ± 23.5*
*P value < 0.05 by Student’s t-test or by chi-square test. HDL, high-density lipoprotein; 
LDL, low-density lipoprotein.
Table 2. Distribution of genotypes and alleles, and linkage disequilibrium (LD) analysis 
for PON1 SNPs 
Parameters 17899insdelTT 17974CT 192QR
Site Intron 5 Intron 5 Exon 6
Major/minor allele insTT/delTT C/T R/Q










   (major:minor allele)
0.63:0.37 0.89:0.11 0.66:0.34





   17899insdelTT
   17974CT










T, thymine; C, cytosine; R, arginine; Q, glutamine; HWE, Hardy-Weinberg equilibrium; 
LD, linkage disequilibrium.
Table 3. Serum paraoxonase and arylesterase activity by PON1 genetic polymorphisms
Genotypes No. (%)
Paraoxonase (unit/L) Arylesterase (unit/mL)
Mean ± SD P value Mean ± SD P value
17899insdelTT
   insTT/insTT
   insTT/delTT
   delTT/delTT
 
  64 (41.8)
  66 (43.2)














   C/C
   C/T+T/T
 
121 (79.1)












   Q/Q
   Q/R
   R/R
 
  19 (12.4)
  65 (42.5)
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was positively associated with triglyceride and HDL-cholesterol 
levels (P = 0.048 and 0.001, respectively) and negatively associ-
ated with age and the 192QR polymorphism in multiple regres-
sion models with serum PON1-arylesterase activity as the de-
pendent variable. These 4 variables explained 32.1% of the vari-
ance of serum PON1-arylesterase activity. The 192QR polymor-
phism accounted for 20.2% of the variance of PON1-arylester-
ase activity and showed the largest effect of any the indepen-
dent variables (Table 4).  
 
DISCUSSION
In this study, serum PON1-arylesterase activity was higher in 
women than men. This gender difference was owing to the low-
er rate of smoking among women compared with men, rather 
than being due to a gender effect. As with previous epidemio-
logic studies (13, 14), our data suggest that smoking decreases 
serum PON1 activity (Tables 1, 4). It concurs with the results of 
an in vitro study in which cigarette smoke extracts inhibited se-
rum PON1 activity through modification of PON’s free thiol res-
idue at amino acid 283 (15).
  The frequency of the 192R allele (66%) in this study was simi-
lar to that of earlier reports on Korean (60%-66%) (16, 17), Japa-
nese (64%-67%) (18, 19), Chinese (65%) (20), and African-Amer-
ican (63%-85%) populations (21, 22), but differed when com-
pared to south-western Korean (30%) (23), Caucasians (27%-
31%) (21, 24) and Hispanic (41%-46%) populations (21, 25).
  As far as we know LD among intronic and exonic polymor-
phisms of the PON1 gene has not been studied till now. Previ-
ous studies have reported LD within the SNPs of the coding re-
gion (55ML and 192QR) or 5´ flanking region (-108CT, -126GC, 
Table 4. Multiple regression analysis of the factors influencing serum PON1 activity
Parameters β S.E. Partial R
2 P value
Model for paraoxonase activity (R
2 = 0.658)
   Age (yr) -0.88 0.52 0.008 0.091
   Smoking (0: never, 1: ever) -45.76 15.98 0.022 0.005
   Triglyceride (mg/dL) 0.17 0.05 0.021 0.002
   HDL-cholesterol (mg/dL) 1.79 0.40 0.039 < 0.001
   Body mass index (kg/m
2) 2.55 1.62 0.006 0.118
   17899insdelTT (0: insTT/insTT,
      1: insTT/delTT, 2: delTT/delTT)
40.93 23.53 0.007 0.084
   17974CT (0: C/C, 1: C/T + T/T) 32.44 13.02 0.018 0.014
   192QR (0: Q/Q, 1: Q/R, 2: R/R) 154.59 24.67 0.537 < 0.001
Model for arylesterase activity (R
2 = 0.371)
   Age (yr) -0.44 0.16 0.039 0.008
   Smoking (0: never, 1: ever) -8.34 4.90 0.015 0.091
   Triglyceride (mg/dL) 0.03 0.02 0.012 0.048
   HDL-cholesterol (mg/dL) 0.50 0.13 0.070 0.001
   Body mass index (kg/m
2) 0.95 0.50 0.022 0.062
   17974CT (0: C/C, 1: C/T + T/T) 6.33 4.03 0.011 0.119
   192QR (0: Q/Q, 1: Q/R, 2: R/R) -15.07 2.46 0.202 < 0.001
S.E., standard error; HDL, high-density lipoprotein; T, thymine; C, cytosine; R, arginine; 
Q, glutamine.
-162AG, -832GA, and -909CG) of PON1 (2, 8). Although our data 
showed LD among tested SNPs, it is difficult to exclude the pos-
sibility that LD was caused by the relatively short physical dis-
tance between the tested SNPs. Since strong LD exists between 
the two-base deletion/insertion polymorphism (17899insdel-
TT) and 192QR, which is one of the most important SNPs deter-
mining PON1 enzyme activity, primers for 192QR genotyping 
should not include the 2-base deletion/insertion polymorphism 
site.
  As in previous studies, the results of this study suggest that the 
192R/R genotype is associated with higher serum paraoxonase 
activity and lower arylesterase activity (2, 3, 9). However, the level 
of serum PON1 activity in our study is not directly comparable 
with those of previously reported data, because of various dif-
ferences in environmental factors (e.g., diet, smoking, alcohol 
consumption, age, and environmental toxin exposure). In ad-
dition, individual HDL level can influence the serum activity of 
PON1, as can the 192QR genetic polymorphism (3, 9). 
  In this study, we first characterized the relationship between 
intronic polymorphisms of PON1 and serum PON1 activity. Our 
results demonstrated that intronic genetic polymorphisms of 
PON1 can also affect serum PON1 activity. Although this effect 
was probably due to LD of the intronic polymorphisms with the 
192QR polymorphism, it cannot be ruled out that intronic SNPs 
of PON1 may directly regulate transcription by alteration of RNA 
elongation, splicing, or maturation (26-28).
  The effect size of the 192QR polymorphism for serum PON1-
paraoxonase activity in this study (53.7%) is similar to those of 
American studies, 48%-59% (25, 29). Our data showed that the 
activity of both serum paraoxonase and arylesterase correlated 
with serum HDL level. Previous studies have reported that HDL 
is an important determinant of serum PON1 enzyme concen-
tration and activity, is related to the release mechanism, and acts 
as the serum transport vector for PON1 (10). Up to about 70% 
of the variance of serum HDL levels is regulated by genetic fac-
tors such as ApoA1, Abca1, Scarb1, cholesterol ester transfer 
protein (Cetp), and endothelial lipase (Lipg) (30). Further study 
is necessary to elucidate the other genetic factors associated 
with serum PON1 level and activity.
  In conclusion, it is suggested that although the PON1 192QR 
SNP is primarily associated with serum PON1 activity, the in-
tronic SNPs (17899insdelTT and 17974CT) of PON1 are also in-
volved in serum PON1 activity, which may be mediated by LD 
among SNPs.
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Effects of Intronic and Exonic Polymorphisms of Paraoxonase 1 (PON1) Gene on 
Serum PON1 Activity in a Korean Population
Sang–Yong Eom, Yun–Sik Kim, Chung–Jong Lee, Chul–Ho Lee, Yong–Dae Kim and Heon Kim
PON1 (paraoxonase 1) is a major anti-atherosclerotic component of high-density lipoprotein (HDL).  We investigated the 
association between 3 polymorphisms of PON1 located in intron 5 (17899insdelTT and 17974CT) and exon 6 (192QR) and serum 
PON1 activity. We found that the 192QR genetic polymorphism is the most important determinant of serum PON1 activity, and 
the intronic polymorphisms, which are closely associated with the 192QR polymorphism, also involved in serum PON1 activity. 
This is the first characterization of the relationship between intronic polymorphisms of PON1 and serum PON1 activity in Korean 
population.